表紙
市場調查報告書
商品編碼
916985

重症肌無力治療的全球市場:治療方法,各最終用途市場規模,佔有率及趨勢分析報告,各市場區隔預測(2019年∼2026年)

Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report by Treatment (Medication, Surgery), by End Use (Hospitals, Clinics), and Segment Forecasts, 2019 - 2026

出版日期: | 出版商: Grand View Research, Inc. | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球重症肌無力(MG)治療市場在預測期間內預計將以7.5%的年複合成長率成長,至2026年達到20億6,000萬美元的規模。罕見疾病的認識的高漲,生技藥品的出現,及免疫療法和免疫抑制劑的採用增加等要素,推進著重症肌無力治療市場。

重症肌無力(MG),是由引起骨骼肌肉衰弱的抗體媒介神經肌肉傳達障礙所引起,稀少的自體免疫障礙。這個疾病相關的障礙,有眼瞼下垂,複視,步行障礙,會話障礙等。 MG的患者,表現不伴隨疼痛的肌肉無力,重複使用導致肌肉惡化,休息便改善。

本報告提供全球重症肌無力(MG)治療市場相關調查分析,市場及產業預測,各市場區隔預測,加上競爭情形相關的系統性資訊。

目錄

第1章 調查方法與範圍

  • 市場區隔和範圍
  • 市場定義
  • 資訊採購
  • 資訊分析
  • 市場定式化、資料的視覺化
  • 資料的檢驗、公開

第2章 摘要整理

  • 市場預測
  • 市場區隔預測
  • 競爭的考察

第3章 市場變數,趨勢及範圍

  • 市場系列預測
  • 市場滲透及成長預測的製圖
  • 法律規範
  • 市場動態
  • 市場分析工具

第4章 競爭分析

  • 各主要市場參與者最新趨勢及影響分析
  • 公司分類
  • 業者情勢
  • 公開企業
  • 非公開企業
  • 供應商排行榜

第5章 各治療法評估及趨勢分析

  • 定義及範圍
  • 市場佔有率分析,2018年及2026年
  • 市場區隔儀表板
  • 全球重症肌無力治療市場,各治療法,2015年∼2026年
  • 市場規模、預測及趨勢分析,2015年∼2026年
    • 藥物治療市場
    • 手術市場
    • 其他

第6章 各最終用途評估及趨勢分析

  • 定義和範圍
  • 市場佔有率分析,2018年及2026年
  • 市場區隔儀表板
  • 全球重症肌無力治療市場,各最終用途,2015年∼2026年
  • 市場規模、預測及趨勢分析,2015年∼2026年
    • 醫院市場
    • 診所市場
    • 其他

第7章 各地區評估及趨勢分析

  • 地區市場概述
  • 各地區市場佔有率及主要企業,2018年
    • 北美
    • 歐洲
    • 中南美
    • 亞太地區
    • 中東、非洲地區
  • 2018年的各國市場佔有率分析
    • 北美
    • 歐洲
    • 中南美
    • 亞太地區
    • 中東、非洲地區
  • 各要因SWOT分析(政治,法律,經濟,技術性)
    • 北美
    • 歐洲
    • 中南美
    • 亞太地區
    • 中東、非洲地區
  • 市場規模、預測,趨勢分析,2018年∼2026年
    • 北美
    • 歐洲
    • 中南美
    • 亞太地區
    • 中東、非洲地區

第8章 公司概要

  • 公司概要
目錄
Product Code: GVR-4-68038-002-6

The global myasthenia gravis treatment market size is expected to reach USD 2.06 billion by 2026 at a CAGR of 7.5% through the forecast period, according to a new report by Grand View Research. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Further Key Findings From the Study Suggest:

  • Medications are expected to obtain the largest market share in the treatment segment. This can be attributed to the high adoption of immunotherapies and the recent approval of promising drugs.
  • Currently, no cure is available for myasthenia gravis, however patients can be treated with medications and surgery for the management of the symptoms.
  • North America is likely to dominate the MG treatment market due high healthcare expenditure and favorable reimbursement scenario
  • The Asia Pacific region is expected to grow at the highest CAGR over the forecast period due to improving healthcare infrastructure and increasing disposable income in the region.

Some of the major companies operating in the market include: Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market segmentation & scope
  • 1.2 Market definition
  • 1.3 Information procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources & third party perspectives
    • 1.3.4 Primary research
  • 1.4 Information analysis
    • 1.4.1 Data analysis models
  • 1.5 Market formulation & data visualization
  • 1.6 Data validation & publishing

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 Myasthenia Gravis Treatment Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Regulatory Framework
  • 3.4 Market Dynamics
    • 3.4.1 Market driver analysis
    • 3.4.2 Market Restraint Analysis
    • 3.4.3 Industry challenges
  • 3.5 Myasthenia Gravis Treatment Market Analysis Tools
    • 3.5.1 Industry analysis - Porter's
      • 3.5.1.1 Supplier Power
      • 3.5.1.2 Buyer Power
      • 3.5.1.3 Substitution Threat
      • 3.5.1.4 Threat from new entrants
      • 3.5.1.5 Competitive Rivalry
    • 3.5.2 PESTEL Analysis
      • 3.5.2.1 Political Landscape
      • 3.5.2.2 Environmental Landscape
      • 3.5.2.3 Social landscape
      • 3.5.2.4 Technology landscape
      • 3.5.2.5 Legal Landscape
    • 3.5.3 Major deals and strategic alliances analysis
      • 3.5.3.1 Joint ventures
      • 3.5.3.2 Mergers and acquisitions
      • 3.5.3.3 Licensing and partnership
      • 3.5.3.4 Technology collaborations
      • 3.5.3.5 Strategic Divestments
    • 3.5.4 Market entry strategies

Chapter 4 Myasthenia Gravis Treatment Market - Competitive Analysis

  • 4.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 4.2 Company Categorization
  • 4.3 Vendor Landscape
    • 4.3.1 List of key distributors and channel partners
    • 4.3.2 Key customers
    • 4.3.3 Key company market share analysis, 2018
  • 4.4 Public Companies
    • 4.4.1 Regional network map
    • 4.4.2 Company market position analysis
    • 4.4.3 Company market share, by region
  • 4.5 Private Companies
    • 4.5.1 List of key emerging companies
    • 4.5.2 Company market position analysis
  • 4.6 Supplier Ranking

Chapter 5 Myasthenia Gravis Treatment Market: Treatment Estimates and Trend Analysis

  • 5.1 Definitions & Scope
  • 5.2 Market Share Analysis, 2018 & 2026
  • 5.3 Segment Dashboard
  • 5.4 Global Myasthenia Gravis Treatment Market, by Treatment, 2015 to 2026
  • 5.5 Market Size & Forecasts and Trend Analyses, 2015 to 2026
    • 5.5.1 Medication Market
      • 5.5.1.1 Medication Market, 2015 to 2026 (USD Million)
    • 5.5.2 Surgery Market
      • 5.5.2.1 Surgery Market, 2015 to 2026 (USD Million)
    • 5.5.3 Others Market
      • 5.5.3.1 Others Market, 2015 to 2026 (USD Million)

Chapter 6 Myasthenia Gravis Treatment Market: End Use Estimates and Trend Analysis

  • 6.1 Definitions & Scope
  • 6.2 Market Share Analysis, 2018 & 2026
  • 6.3 Segment Dashboard
  • 6.4 Global Myasthenia Gravis Treatment Market, by End Use, 2015 to 2026
  • 6.5 Market Size & Forecasts and Trend Analyses, 2015 to 2026
    • 6.5.1 Hospitals Market
      • 6.5.1.1 Hospitals Market, 2015 to 2026 (USD Million)
    • 6.5.2 Clinics Market
      • 6.5.2.1 Clinics Market, 2015 to 2026 (USD Million)
    • 6.5.3 Others Market
      • 6.5.3.1 Others Market, 2015 to 2026 (USD Million)

Chapter 7 Myasthenia Gravis Treatment Market: Regional Estimates & Trend Analysis

  • 7.1 Regional Market Snapshot
  • 7.2 Regional Market Share and Leading Players, 2018
    • 7.2.1 North America
    • 7.2.2 Europe
    • 7.2.3 Latin America
    • 7.2.4 Asia Pacific
    • 7.2.5 Middle East & Africa
  • 7.3 Market Share Analysis by Country, 2018
    • 7.3.1 North America
      • 7.3.1.1 U.S.
      • 7.3.1.2 Canada
    • 7.3.2 Europe
      • 7.3.2.1 UK
      • 7.3.2.2 Germany
      • 7.3.2.3 Spain
      • 7.3.2.4 France
      • 7.3.2.5 Italy
      • 7.3.2.6 Russia
    • 7.3.3 Latin America
      • 7.3.3.1 Brazil
      • 7.3.3.2 Mexico
      • 7.3.3.3 Argentina
    • 7.3.4 Asia Pacific
      • 7.3.4.1 Japan
      • 7.3.4.2 China
      • 7.3.4.3 India
      • 7.3.4.4 South Korea
      • 7.3.4.5 Singapore
      • 7.3.4.6 Australia
    • 7.3.5 Middle East & Africa
      • 7.3.5.1 South africa
      • 7.3.5.2 Saudi Arabia
      • 7.3.5.3 UAE
  • 7.4 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
    • 7.4.1 North America
    • 7.4.2 Europe
    • 7.4.3 Latin America
    • 7.4.4 Asia Pacific
    • 7.4.5 Middle East & Africa
  • 7.5 Market Size & Forecasts, and Trend Analysis, 2018 to 2026
    • 7.5.1 North America
      • 7.5.1.1 North America Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.1.2 U.S.
      • 7.5.1.2.1 U.S. Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.1.3 Canada
      • 7.5.1.3.1 Canada Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
    • 7.5.2 Europe
      • 7.5.2.1 Europe Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.2.2 UK
      • 7.5.2.2.1 UK Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.2.3 Germany
      • 7.5.2.3.1 Germany Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.2.4 Spain
      • 7.5.2.4.1 Spain Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.2.5 France
      • 7.5.2.5.1 France Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.2.6 Italy
      • 7.5.2.6.1 Italy Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.2.7 Russia
      • 7.5.2.7.1 Russia Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
    • 7.5.3 Latin America
      • 7.5.3.1 Latin America Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.3.2 Brazil
      • 7.5.3.2.1 Brazil Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.3.3 Mexico
      • 7.5.3.3.1 Mexico Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.3.4 Argentina
      • 7.5.3.4.1 Argentina Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
    • 7.5.4 Asia Pacific
      • 7.5.4.1 Asia Pacific Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.4.2 Japan
      • 7.5.4.2.1 Japan Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.4.3 China
      • 7.5.4.3.1 China Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.4.4 India
      • 7.5.4.4.1 India Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.4.5 South Korea
      • 7.5.4.5.1 South Korea Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.4.6 Singapore
      • 7.5.4.6.1 Singapore Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.4.7 Australia
      • 7.5.4.7.1 Australia Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
    • 7.5.5 Middle East & Africa
      • 7.5.5.1 Middle East & Africa Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.5.2 South Africa
      • 7.5.5.2.1 South Africa Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.5.3 Saudi Arabia
      • 7.5.5.3.1 Saudi Arabia Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)
      • 7.5.5.4 UAE
      • 7.5.5.4.1 UAE Market Size & Forecasts and Trend Analysis, 2015 to 2026 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Company Profiles
    • 8.1.1 Alexion Pharmaceutical Inc.
      • 8.1.1.1 Company overview
      • 8.1.1.2 Financial performance
      • 8.1.1.3 Product benchmarking
      • 8.1.1.4 Strategic initiatives
    • 8.1.2 Grifols SA
      • 8.1.2.1 Company overview
      • 8.1.2.2 Financial performance
      • 8.1.2.3 Product benchmarking
      • 8.1.2.4 Strategic initiatives
    • 8.1.3 Avadel Pharmaceuticals, Plc.
      • 8.1.3.1 Company overview
      • 8.1.3.2 Financial performance
      • 8.1.3.3 Product benchmarking
      • 8.1.3.4 Strategic initiatives
    • 8.1.4 Novartis
      • 8.1.4.1 Company overview
      • 8.1.4.2 Financial performance
      • 8.1.4.3 Product benchmarking
      • 8.1.4.4 Strategic initiatives
    • 8.1.5 Pfizer, Inc.
      • 8.1.5.1 Company overview
      • 8.1.5.2 Financial performance
      • 8.1.5.3 Product benchmarking
      • 8.1.5.4 Strategic initiatives
    • 8.1.6 AbbVie Inc.
      • 8.1.6.1 Company overview
      • 8.1.6.2 Financial performance
      • 8.1.6.3 Product benchmarking
      • 8.1.6.4 Strategic initiatives
    • 8.1.7 F.Hoffmann-La Roche AG
      • 8.1.7.1 Company overview
      • 8.1.7.2 Financial performance
      • 8.1.7.3 Product benchmarking
      • 8.1.7.4 Strategic initiatives
    • 8.1.8 GlaxoSmithKline Plc.
      • 8.1.8.1 Company overview
      • 8.1.8.2 Financial performance
      • 8.1.8.3 Product benchmarking
      • 8.1.8.4 Strategic initiatives
    • 8.1.9 Bausch Health Companies Inc.
      • 8.1.9.1 Company overview
      • 8.1.9.2 Financial performance
      • 8.1.9.3 Product benchmarking
      • 8.1.9.4 Strategic initiatives
    • 8.1.10 Shire plc
      • 8.1.10.1 Company overview
      • 8.1.10.2 Financial performance
      • 8.1.10.3 Product benchmarking
      • 8.1.10.4 Strategic initiatives

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 Global myasthenia gravis treatment market, by region, 2015 - 2026 (USD Million)
  • Table 4 Global myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 5 Global myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 6 North America myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 7 North America myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 8 North America myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 9 U.S. myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 10 U.S. myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 11 U.S. myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 12 Canada myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 13 Canada myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 14 Canada myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 15 Europe myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 16 Europe myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 17 Europe myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 18 Germany myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 19 Germany myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 20 Germany myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 21 UK myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 22 UK myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 23 UK myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 24 France myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 25 France myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 26 France myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 27 Spain myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 28 Spain myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 29 Spain myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 30 Italy myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 31 Italy myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 32 Italy myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 33 Russia myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 34 Russia myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 35 Russia myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 36 Asia Pacific myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 37 Asia Pacific myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 38 Asia Pacific myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 39 Japan myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 40 Japan myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 41 Japan myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 42 China myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 43 China myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 44 China myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 45 India myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 46 India myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 47 India myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 48 South Korea myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 49 South Korea myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 50 South Korea myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 51 Singapore myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 52 Singapore myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 53 Singapore myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 54 Australia myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 55 Australia myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 56 Australia myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 57 Latin America myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 58 Latin America myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 59 Latin America myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 60 Brazil myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 61 Brazil myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 62 Brazil myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 63 Mexico myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 64 Mexico myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 65 Mexico myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 66 Argentina myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 67 Argentina myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 68 Argentina myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 69 MEA myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 70 MEA myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 71 MEA myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 72 South Africa myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 73 South Africa myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 74 South Africa myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 75 Saudi Arabia myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 76 Saudi Arabia myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 77 Saudi Arabia myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Table 78 UAE myasthenia gravis treatment market, by country, 2015 - 2026 (USD Million)
  • Table 79 UAE myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Table 80 UAE myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)

List of Figures

  • Fig. 1 Myasthenia gravis treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Myasthenia gravis treatment market snapshot (2018)
  • Fig. 9 Competitive insights (2018)
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Myasthenia gravis treatment market driver impact
  • Fig. 14 Myasthenia gravis treatment market restraint impact
  • Fig. 15 Myasthenia gravis treatment industry challenges
  • Fig. 16 Porter's five forces analysis
  • Fig. 17 SWOT analysis, by factor (Political & legal, economic and technological)
  • Fig. 18 Strategic alliance analysis
  • Fig. 19 Recent developments & impact analysis, by key market participants
  • Fig. 20 Key company market share analysis, 2018
  • Fig. 21 Company market share/ranking, by region
  • Fig. 22 Company market position analysis
  • Fig. 23 Supplier ranking
  • Fig. 24 Myasthenia gravis treatment market share analysis, by treatment, 2018 & 2026 (%)
  • Fig. 25 Segment dashboard
  • Fig. 26 Global myasthenia gravis treatment market, by treatment, 2015 - 2026 (USD Million)
  • Fig. 27 Medication market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 28 Surgery market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 29 Others market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 30 Myasthenia gravis treatment market share analysis, by end use, 2018 & 2026 (%)
  • Fig. 31 Segment dashboard
  • Fig. 32 Global myasthenia gravis treatment market, by end use, 2015 - 2026 (USD Million)
  • Fig. 33 Hospitals market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 34 Clinics market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 35 Others market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 36 Myasthenia gravis treatment market: Snapshot, 2018
  • Fig. 37 North America myasthenia gravis treatment market share and leading players, 2018
  • Fig. 38 Europe myasthenia gravis treatment market share and leading players, 2018
  • Fig. 39 Asia Pacific myasthenia gravis treatment market share and leading players, 2018
  • Fig. 40 Latin America myasthenia gravis treatment market share and leading players, 2018
  • Fig. 41 Middle East and Africa myasthenia gravis treatment market share and leading players, 2018
  • Fig. 42 North America myasthenia gravis treatment market share analysis by country, 2018
  • Fig. 43 Europe myasthenia gravis treatment market share analysis by country, 2018
  • Fig. 44 Asia Pacific myasthenia gravis treatment market share analysis by country, 2018
  • Fig. 45 Latin America myasthenia gravis treatment market share analysis by country, 2018
  • Fig. 46 Middle East and Africa myasthenia gravis treatment market share analysis by country, 2018
  • Fig. 47 North America SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 48 Europe SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 49 Asia Pacific SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 50 Latin America SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 51 Middle East and Africa SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 52 North America myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 53 U.S. myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 54 Canada myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 55 Europe myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 56 UK myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 57 Germany myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 58 Spain myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 59 France myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 60 Italy myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 61 Russia myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 62 Asia Pacific myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 63 China myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 64 Japan myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 65 India myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 66 South Korea myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 67 Singapore myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 68 Latin America myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 69 Brazil myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 70 Mexico myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 71 Argentina myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 72 Middle East and Africa myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 73 South Africa myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 74 Saudi Arabia myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)
  • Fig. 75 UAE myasthenia gravis treatment market size & forecasts and trend analysis, 2015 to 2026 (USD Million)